Recent Price Movement and Market Context
On 17 Mar 2026, Themis Medicare’s share price touched an intraday low of Rs.73.63, representing a 3.46% drop on the day and a 1.43% decline compared to the previous close. This marks the lowest price level for the stock in the past 52 weeks, a notable milestone that underscores the sustained pressure on the company’s valuation. Over the last three trading sessions, the stock has declined by 11.11%, signalling a consistent downtrend.
The stock’s performance today notably lagged behind its Pharmaceuticals & Biotechnology sector peers, underperforming by 3.44%. Meanwhile, the broader market, represented by the Sensex, opened higher at 75,826.68 points with a gain of 0.43%, though it currently trades marginally up by 0.06% at 75,550.38. Despite the Sensex’s modest gains, Themis Medicare’s shares continue to trade below all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – indicating a bearish technical setup.
Long-Term Performance and Valuation Concerns
Themis Medicare’s one-year stock return stands at -47.43%, a stark contrast to the Sensex’s positive 1.86% return over the same period. The stock’s 52-week high was Rs.179.25, highlighting the extent of the decline from its peak. This underperformance extends beyond the last year, with the company lagging behind the BSE500 index over the past three years, one year, and three months.
From a valuation perspective, the company is classified as a micro-cap with a Mojo Score of 26.0 and a Mojo Grade of Strong Sell, upgraded from a Sell rating on 1 Feb 2025. The downgrade reflects concerns about the company’s growth trajectory and profitability metrics. The stock is considered risky relative to its historical valuations, with profits falling by 135.9% over the past year, further weighing on investor confidence.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Financial Performance Highlights
Themis Medicare’s recent financial results have shown subdued growth. For the latest six-month period, the company reported a Profit After Tax (PAT) of Rs.7.32 crores, reflecting a decline of 50.60% compared to the previous corresponding period. Net sales for the same period stood at Rs.168.12 crores, down by 20.25%. These figures indicate a contraction in both top-line and bottom-line performance.
Return on Capital Employed (ROCE) for the half-year period was negative at -3.47%, signalling challenges in generating adequate returns from the capital invested. Over the last five years, operating profit has deteriorated at an annual rate of -185.54%, underscoring the company’s struggles to sustain profitable growth over the long term.
Risk Profile and Shareholding
The stock’s risk profile is elevated, with its current trading levels reflecting a discount relative to historical valuations. Despite the company’s micro-cap status, domestic mutual funds hold no stake in Themis Medicare, which may indicate limited institutional confidence or comfort with the company’s current valuation and business outlook.
On a positive note, the company maintains a relatively strong ability to service its debt obligations, with a Debt to EBITDA ratio of 0.86 times. This suggests manageable leverage levels despite the financial headwinds.
Technical Indicators and Market Sentiment
Technical analysis of Themis Medicare’s stock reveals a predominantly bearish outlook. Key indicators such as the Moving Average Convergence Divergence (MACD) are bearish on both weekly and monthly timeframes. Bollinger Bands also signal bearish momentum, while the daily moving averages confirm the downward trend. Other technical tools, including the Know Sure Thing (KST) indicator and Dow Theory, reflect weak or mildly bearish trends on weekly and monthly charts. The On-Balance Volume (OBV) indicator shows no clear trend weekly but mildly bearish signals monthly, suggesting subdued buying interest.
These technical signals align with the stock’s recent price action, reinforcing the current downtrend and the challenges faced by Themis Medicare in regaining upward momentum.
Considering Themis Medicare Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Summary of Market and Sector Position
The Pharmaceuticals & Biotechnology sector, in which Themis Medicare operates, has seen mixed performance recently. While mega-cap stocks in the sector and broader market have shown resilience, Themis Medicare’s micro-cap status and financial metrics have contributed to its relative underperformance. The stock’s current trading below all major moving averages contrasts with the Sensex’s broader market gains, which are led by mega-cap companies.
Given the company’s financial results, valuation concerns, and technical indicators, Themis Medicare’s stock remains under pressure, reflected in its new 52-week low and ongoing negative returns over multiple time horizons.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
